Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer
- 7 September 2010
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 103 (6), 787-795
- https://doi.org/10.1038/sj.bjc.6605827
Abstract
Interleukin-6 (IL-6) binds both the membrane and soluble forms of the IL-6 receptor (sIL-6R), which induces a complex with gp130, and proliferation of tumour cells. The aim of this study is to clarify the relationship between tumoral sIL-6R expression and disease progression in colorectal cancer patients. We measured tissue concentrations of sIL-6R in tumour and normal mucosa from 161 colorectal cancer patients undergoing surgery, and in supernatants from colon cancer cell lines. The expression of IL-6, IL-6R and gp130 was evaluated by immunohistochemical analysis. Loss of tumour expression of sIL-6R as defined by sIL-6R Ca/N ratio <1.0 was significantly associated with factors reflecting disease progression, and was an independent prognostic factor not only in all the patients in this study, but also in the patients with curative intent. Colon cancer cell lines produced sIL-6R in vitro, and the production of sIL-6R in cancer cell lines was stimulated by cytokine stimulation. Immunohistochemistry revealed that loss of tumour expression of sIL-6R was significantly inversely correlated with intense IL-6 expression in the cytoplasm of cancer cells. In addition, tumoral IL-1beta expression was significantly correlated with sIL-6R expression. Loss of tumour expression of sIL-6R is associated with colorectal cancer disease progression.Keywords
This publication has 40 references indexed in Scilit:
- Comparison of the Prognostic Value of Inflammation-Based Pathologic and Biochemical Criteria in Patients Undergoing Potentially Curative Resection for Colorectal CancerAnnals of Surgery, 2010
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated CancerCancer Cell, 2009
- Interleukin-6 and Soluble Interleukin-6 Receptor Levels as Markers of Disease Extent and Prognosis in NeuroblastomaClinical Cancer Research, 2008
- Interleukin‐6 Trans‐Signalling in Chronic Inflammation and CancerScandinavian Journal of Immunology, 2006
- Bone Marrow Mesenchymal Stem Cells Provide an Alternate Pathway of Osteoclast Activation and Bone Destruction by Cancer CellsCancer Research, 2005
- TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-SignalingImmunity, 2004
- NUTRITIONAL STATUS AND POSTOPERATIVE CYTOKINE RESPONSE IN COLORECTAL CANCER PATIENTSCytokine, 2000
- gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINESAnnual Review of Immunology, 1997
- Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomasFEBS Letters, 1989
- Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomasNature, 1988